IDEXX Laboratories, Inc. $IDXX Shares Sold by First Trust Advisors LP

Posted by Brenda Bartman on Jul 24th, 2026

First Trust Advisors LP lowered its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 0.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 234,653 shares of the company’s stock after selling 1,458 shares during the quarter. First Trust Advisors LP owned 0.30% of IDEXX Laboratories worth $131,849,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of IDXX. SHP Wealth Management purchased a new stake in shares of IDEXX Laboratories in the 4th quarter valued at approximately $26,000. Virtus Advisers LLC purchased a new stake in shares of IDEXX Laboratories during the 3rd quarter worth $26,000. WealthCollab LLC purchased a new stake in shares of IDEXX Laboratories during the 2nd quarter worth $30,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of IDEXX Laboratories during the third quarter worth $36,000. Finally, Mowery & Schoenfeld Wealth Management LLC increased its holdings in IDEXX Laboratories by 58.8% in the fourth quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock valued at $37,000 after buying an additional 20 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have commented on IDXX. Weiss Ratings lowered shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Tuesday, July 14th. Wall Street Zen downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Stifel Nicolaus cut their price target on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a report on Tuesday, March 31st. Citigroup began coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price objective on the stock. Finally, UBS Group dropped their target price on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a report on Tuesday, April 28th. Six investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $751.00.

Read Our Latest Analysis on IDXX

IDEXX Laboratories Stock Down 1.0%

IDXX stock opened at $539.36 on Friday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82. The company’s 50 day simple moving average is $555.96 and its 200-day simple moving average is $595.77. IDEXX Laboratories, Inc. has a 12 month low of $518.55 and a 12 month high of $769.98. The firm has a market capitalization of $42.54 billion, a PE ratio of 39.72, a P/E/G ratio of 2.98 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last posted its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. The firm had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.IDEXX Laboratories’s revenue was up 14.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Equities analysts expect that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

About IDEXX Laboratories

(Free Report)

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.